Sarah Cannon, the Cancer Institute of HCA Healthcare, announced recently that Stephen A. Strickland, Jr, MD, MSCI, has been named the Director of Leukemia Research for the Transplant & Cellular Therapy Network. In this role, Dr. Strickland provides scientific leadership and oversees Sarah Cannon’s portfolio of clinical trials in leukemia, myelodysplastic syndromes, and related diseases.
“The Sarah Cannon Transplant & Cellular Therapy Network has a robust acute leukemia and myeloid disease clinical research program and cares for more than 1,800 leukemia patients yearly,” said Navneet Majhail, MD, MS, FASTCT, Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant & Cellular Therapy Network. “Dr. -Strickland’s expertise and leadership within the acute leukemia field will further advance our mission to bring these novel therapies to our patients closer to home.”
Dr. Strickland’s Background
Dr. Strickland joined Sarah Cannon from Vanderbilt University Medical Center, where he served as Clinical Director for Acute Leukemia and Malignant Hematology and Stem Cell Transplant Medical Director. An internationally respected leukemia researcher with more than 100 peer-reviewed scientific publications and abstracts, he presently serves on several leukemia-related committees within the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network.
Dr. Strickland received his Doctor of Medicine from Louisiana State University School of Medicine in New Orleans and completed his internship/residency (internal medicine), clinical fellowship (hematology/oncology), and a Master of Science in Clinical Investigation at Vanderbilt University Medical Center. In addition to his role with the Sarah Cannon Transplant & Cellular Therapy Network, he will serve as leukemia specialist for the Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial in Nashville.
